{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:26:08Z","timestamp":1760297168791},"reference-count":13,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1080\/1042819032000159852","type":"journal-article","created":{"date-parts":[[2004,4,21]],"date-time":"2004-04-21T14:29:37Z","timestamp":1082557777000},"page":"1289-1291","source":"Crossref","is-referenced-by-count":4,"title":["Gemcitabine and Oxaliplatinum: An Effective Regimen in a Patient with Progressive Refractory Mantle Cell Lymphoma"],"prefix":"10.1080","volume":"45","author":[{"given":"A","family":"Sampol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Galm\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Besalduch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2009,8,3]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1182\/blood.V87.11.4483.bloodjournal87114483","volume":"0","author":"Weisenburger D.D","year":"1996","journal-title":"Blood"},{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/JCO.1998.16.1.3","author":"Coiffier B","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"CIT0003","first-page":"263","volume":"6","author":"Stewart D.A.","year":"1995","journal-title":"\"The role of high dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma\", Annals of Oncology"},{"key":"CIT0004","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","volume":"16","author":"Freedman A.","year":"1998","journal-title":"no evidence for long-term remission\", Journal of Clinical Oncology"},{"key":"CIT0005","first-page":"1293","volume":"10","author":"Khouri IF.","year":"1999","journal-title":"Molecu-lar remissions and evidence of graft-versus-malignancy\", Annals of Oncology"},{"key":"CIT0006","first-page":"1351 \u2014 1353","volume":"9","author":"Zinzani P.L.","year":"1998","journal-title":"\"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients\", Annals of Oncology"},{"key":"CIT0007","first-page":"3786 \u2014 3792","volume":"17","author":"Fossa A.","year":"1999","journal-title":"\"Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-hodgIchis lymphoma\", Journal of Clinical Oncology"},{"key":"CIT0008","first-page":"351 \u2014 354","volume":"10","author":"Germann N.","year":"1999","journal-title":"\"Preliminary results on the activity of oxaliplatin (L-OHP) in refractory\/recurrent non-Hodgkin's lymphoma patients\", Annals of Oncology"},{"key":"CIT0009","first-page":"304","volume":"14","author":"Mavroudis D.","year":"2003","journal-title":"\"A dose-escalation and pharmacokinetic study of gemcitabine and oxalipla-tin in patients with advanced solid tumors\", Annals of Oncology"},{"key":"CIT0010","first-page":"711 \u2014 717","volume":"3","author":"Rodriguez J.","year":"1992","journal-title":"\"A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on 'tumor score',\" Annals of Oncology"},{"key":"CIT0011","first-page":"3803","volume":"16","author":"Khouri I.","year":"1998","journal-title":"an active regimen for aggressive mantle cell lymphoma\", Journal of Clinical Oncology"},{"key":"CIT0012","first-page":"S26\u2014S34","volume":"88","author":"Raymond E.","year":"2001","journal-title":"\"[Preclinical studies of oxaliplatin in combination chemotherapy]\", Bulletin du Cancer"},{"key":"CIT0013","first-page":"1512 \u2014 1518","volume":"20","author":"Louvet C.","year":"2002","journal-title":"final results of a GERCOR multicenter phase II study\", Journal of Clinical Oncology"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1042819032000159852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T16:44:36Z","timestamp":1585759476000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1042819032000159852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":13,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2009,8,3]]},"published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1080\/1042819032000159852"],"URL":"https:\/\/doi.org\/10.1080\/1042819032000159852","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}